Repligen
Waltham · Founded 1981
About Repligen
Repligen Corporation is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical component of Protein A resins that are used to separate and purify monoclonal antibody therapeutics. Our ATF (Alternating Tangential Flow) systems and our growth factor products are used to increase product yield during the fermentation stage of biologic drug manufacturing. In addition, we developed and market an innovative line of “ready-to-use” chromatography columns under our OPUS® and MediaScout® brands that we deliver pre-packed with our customers’ choice of resin. Repligen’s corporate headquarters are in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA, Lund, Sweden and Weingarten, Germany.
Company Facts
- Founded: 1981
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1,001 – 5,000
- Estimated revenue: $500K – $1M
- Total funding: $1.3B
- Funding stage: IPO
- Last round: Post-IPO Debt (Dec 2023)
- Ticker: nasdaq:RGEN
- Website: repligen.com
- Phone: +1 781-250-0111
Industries & Categories
Analytics, Biotechnology, Consumer Goods, Health Care, Manufacturing
Social Profiles
Canonical: https://fsome.com/organization/repligen-78121 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.